XML 56 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
 6 Months Ended
Jul. 03, 2021
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring and Nonrecurring Basis
The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
July 3, 2021December 31, 2020
Level 1Level 2Level 3Level 1Level 2Level 3
Measured at fair value on a recurring basis:
Assets:
Investment securities
$1.6 $— $— $2.5 $— $— 
Foreign currency forward contracts
— 5.7 — — 9.8 — 
Cross-currency swap
— 4.2 — — 6.3 — 
Total assets$1.6 $9.9 $— $2.5 $16.1 $— 
Liabilities:
Foreign currency forward contracts$— $2.7 $— $— $7.9 $— 
Total liabilities$— $2.7 $— $— $7.9 $— 
Measured at fair value on a non-recurring basis:
Assets:
Assets held for sale, net(1)
$— $— $1,621.0 $— $— $— 
Total assets$— $— $1,621.0 $— $— $— 
(1)     We measured the assets held for sale for impairment purposes and recorded a total impairment of $158.6 million (refer to Note 9).
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
The table below summarizes the change in fair value of the Royalty Pharma contingent milestone (in millions):
Three Months EndedSix Months Ended
June 27,
2020		June 27,
2020
Beginning balance$96.9 $95.3 
Change in fair value2.1 3.7 
Ending balance$99.0 $99.0 
Schedule of Fair Value Assumptions The table below represents the volatility and rate of return:
Three Months Ended
June 27,
2020
Volatility37.5 %
Rate of return6.91 %
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments
Our fixed rate long-term debt consisted of the following (in millions):
July 3,
2021		December 31,
2020
Level 1Level 2Level 1Level 2
Public Bonds
Carrying Value (excluding discount)$2,760.0 $— $2,760.0 $— 
Fair value$2,946.3 $— $3,031.1 $— 
Private placement note
Carrying value (excluding premium)$— $160.2 $— $164.9 
Fair value$— $172.0 $— $177.5